TY  - JOUR
A1  - Rabe, Thomas
A1  - Sänger, Nicole
A1  - Ebert, Andreas D.
A1  - Römer, Thomas
A1  - Tinneberg, Hans-Rudolf
A1  - Wilde, Rudy Leon de
A1  - Wallwiener, Markus
T1  - Selective progesterone receptor modulators for the medical treatment of uterine fibroids with a focus on ulipristal acetate
T2  - BioMed research international
N2  - Uterine fibroids are the most frequent benign tumours in women of child-bearing age. Their symptoms are diverse and the quality of life of the women affected can be significantly impaired. While treatment to date has been primarily by means of surgical intervention, selective progesterone receptor modulators (SPRMs) open up new medication-based treatment options. EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has recently completed its review of ESMYA® (ulipristal acetate, 5 mg), following reports of serious liver injury, including liver failure leading to transplantation in postmarketing settings. We will provide some information on the PRAC’s recommendations to minimize this risk. Nevertheless, the effectiveness and safety of the SPRM ulipristal acetate (UPA), both with regard to preoperative administration and with regard to an intermittent administration as long-term treatment for patients with symptomatic uterine fibroids, have been shown in several clinical studies (PEARL I–IV).
Y1  - 2018
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/54308
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-543082
SN  - 2314-6141
SN  - 2314-6133
N1  - Corrigendum erschienen in: BioMed research international, 2018, Art. 6124628, doi:10.1155/2018/6124628
N1  - Copyright © 2018 Tomas Rabe et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
VL  - 2018
IS  - Art. 1374821
SP  - 1
EP  - 12
PB  - Hindawi
CY  - New York [u. a.]
ER  -